The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. We have just obtained our CE-IVD Mark for the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX) which detects viruses and bacteria causing respiratory tract infections, the only solution of this kind in Europe. See more >>

News

2026.03.19

Genomtec plans to issue shares. The proceeds will be used to support the M&A process and commercialize projects. The company has concluded an investment agreement with a key shareholder.

Genomtec S.A. on April 13, 2026, at which the Shareholders will vote on an increase in the Company’s share capital through the issue of up to 2 million new series R shares and up to 204,000 series S shares, excluding pre-emptive rights. Genomtec intends to use the funds raised from the new share issue primarily […]

2026.02.12

Genomtec lines up technology trials with potential Asian partners during M&A efforts

Genomtec S.A. started key preparatory activities related to planned testing of Genomtec diagnostic devices in Asia. These activities are directly related to the ongoing M&A process and are a response to the demand expressed by potential partners in this region. The current phase of preparatory work for the tests is organizational and analytical in nature […]

2025.07.31

Genomtec’s Supervisory Board appointed Leroy Huntley to the Company’s Management Board

Genomtec S.A. announced the appointment of Mr. Leroy Huntley to the Company’s Management Board on July 30, 2025, with effect from August 1, 2025. Leroy Huntley serves as Chief Technology Officer (CTO) at Genomtec and has been associated with the Company since 2022. His appointment strengthens the Management Board’s competences at a key moment for […]

Awards